Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
Simran Kalsi, Amanda L. Galenkamp, Rohit Singh, Atulya Aman Khosla, Peter McGranaghan, Jessica Cintolo-Gonzalez · 2024
Read Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review by Simran Kalsi, Amanda L. Galenkamp, Rohit Singh, Atulya Aman Khosla, Peter McGranaghan, Jessica Cintolo-Gonzalez (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646270.txt.
Description
Simran Kalsi and co-authors review therapies injected straight into melanoma tumors, in this 2024 paper. Skin melanoma is rising worldwide and can return in stubborn patches between the first site and the lymph nodes. Surgery still anchors care for such spread. Injected therapies offer a newer tool for spots that cannot be cut out, working by rousing the immune system inside the tumor itself.
The review centers on T-VEC, a modified virus that infects tumor cells and flags them for immune attack. It then surveys the wider field of injected immune therapies now in trials. The authors weigh where these treatments fit beside surgery and whole-body drugs, and what future uses may look like. For patients whose disease sits in reach of a needle, the field is moving fast.
Catalog record
| CREATOR | Simran Kalsi, Amanda L. Galenkamp, Rohit Singh, Atulya Aman Khosla, Peter McGranaghan, Jessica Cintolo-Gonzalez |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |